Blood-based gene detection of non-small cell lung cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention introduces a minimally invasive, blood-based method for detecting non-small cell lung cancer (NSCLC) using gene expression profiling. By measuring the abundance of at least 5 specific RNA molecules in a blood sample and analyzing their expression levels with the aid of trained classification algorithms (such as support vector machines), the method determines whether an individual has NSCLC. The invention also includes diagnostic kits and microarrays designed for this purpose, allowing for early and accurate cancer detection.

Use CasesContent extracted from patent full text and abstract with AI.

• Early detection of non-small cell lung cancer in at-risk populations (e.g., smokers or individuals with a family history) through routine blood tests.
• Supplementary diagnostic tool to imaging (CT, X-ray) for lung cancer screening programs.
• Monitoring of NSCLC patients for disease recurrence or response to therapy.
• Research into gene expression changes associated with NSCLC and immune system interactions.
• Development of blood-based home screening kits or point-of-care diagnostics for lung cancer.

BenefitsContent extracted from patent full text and abstract with AI.

• Minimally invasive compared to traditional biopsy or imaging-based methods, requiring only a blood sample.
• Allows for early detection of NSCLC, potentially before symptoms appear, improving survival chances.
• High accuracy (sensitivity and specificity) as validated in independent patient cohorts.
• Can differentiate NSCLC cases from healthy controls and individuals with other diseases.
• Suitable for repeated testing and monitoring, making it ideal for ongoing surveillance of high-risk individuals or patients.
• Reduces the need for more expensive or invasive procedures unless indicated by a positive test result.
• Potential for automation and scalability using microarrays, PCR, or sequencing, supporting high-throughput clinical workflows.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides a method for early detection of non-small cell lung cancer based on the abundance of RNAs from blood samples as well as diagnostic tools such as kits and arrays suitable for such method.